Article
Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial…
Read More
Excerpt from the Press Release: PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer…
Read More
Studies will assess ST-067 in acute myeloid leukemia or myelodysplastic syndrome and in multiple myeloma Preclinical data to be presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition support the potential therapeutic use of ST-067 in hematologic cancers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.–(BUSINESS…
Read More
More than 20 presentations from top academic and pharma institutions worldwide will demonstrate how innovations like Mission Bio’s Tapestri Platform are driving breakthroughs in hematology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 5, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of…
Read More
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Excerpt from the Press Release: BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to…
Read More
Collaboration utilizes PeriNess’ expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications Excerpt from the Press Release: FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to…
Read More
Excerpt from the Press Release: LONDON and CAMBRIDGE, Mass., Dec. 6, 2024 /PRNewswire/ — Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today announced the presentation of 3-month interim safety and efficacy results of the…
Read More
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib)in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the…
Read More
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers; Observational Natural History and Seroprevalence Study of PKP2-associated ARVC Adults Continues Enrollment at 20 Clinical Sites in the U.S., UK and Europe Initial Clinical Data for RIDGE-1…
Read More